Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
C. Kasap, A. Izgutdina, B. Patino-Escobar, A. Kang, N. Chilakapati, N. Akagi, H. Johnson, T. Rashid, J. Werner, A. Barpanda, H. Geng, Y.-H. T. Lin, S. Rampersaud, D. Gil-Alos, A. Sobh, , A. Wiita
Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.
bioRxiv · Feb 24, 2024Cancer Biology
C. Durfee, N. A. Temiz, R. Levin-Klein, P. Argyris, L. Alsoe, S. Carracedo, A. Alonso, J. Proehl, A. Holzhauer, Z. Seeman, Y.-H. T. Lin, R. I. Vogel, R. Sotillo, H. Nilsen, R. Harris
This study shows that human APOBEC3B causes tumor heterogeneity and metastases in mice, with increased C-to-T mutations and structural variations.
bioRxiv · Feb 24, 2023 · PreprintCancer Biology
T. A. Solvik, T. A. Nguyen, Y.-H. T. Lin, T. Marsh, E. J. Huang, A. P. Wiita, J. Debnath, A. M. Leidal
This study identifies a secretory autophagy pathway that releases autophagy cargo receptors via extracellular vesicles when endolysosomal function is inhibited or autophagosome maturation is disrupted.
bioRxiv · Aug 12, 2021Cell Biology
P. Choudhry, C. Kasap, B. Patino Escobar, O. Gugliemini, H. Geng, V. Sarin, A. Kang, A. Kishishita, S. Rampersaud, L. Sarah, Y.-H. T. Lin, N. Paranjape, P. Ramkumar, M. Marcoulis, D. Wang, , A. Wiita
This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.
bioRxiv · Aug 4, 2021 · PreprintCancer Biology
I. D. Ferguson, B. P. Escobar, S. T. Tuomivaara, Y.-H. T. Lin, M. A. Nix, K. K. Leung, M. Hale, P. Choudhry, A. Lopez-Girona, E. Ramos, S. W. Wong, J. L. Wolf, T. G. Martin, N. Shah, S. Vandenberg, , A. P. Wiita
This study defines the myeloma cell surface proteome, identifies therapeutic targets and resistance biomarkers, and presents a miniaturized surface proteomics protocol.
bioRxiv · Jan 17, 2021Cancer Biology
I. D. Ferguson, Y.-H. T. Lin, C. Lam, H. Shao, M. Hale, K. M. Tharp, M. C. Mariano, V. Steri, D. Wang, P. Phojanokong, S. T. Tuomivaara, B. Hann, C. Driessen, B. V. Ness, J. E. Gestwicki, A. P. Wiita
This study identifies allosteric HSP70 inhibitors that overcome proteasome inhibitor resistance in multiple myeloma by targeting mitochondrial HSPA9 and disrupting mitoribosome stability.
bioRxiv · Apr 21, 2020Cancer Biology
X. Guo, G. Aviles, Y. Liu, R. Tian, B. A. Unger, Y.-H. T. Lin, A. P. Wiita, K. Xu, M. A. Correia, M. Kampmann
The paper identifies OMA1, DELE1, and HRI as a pathway that relays mitochondrial dysfunction to the integrated stress response, showing its role in activating eIF2 kinase activity and potential therapeutic relevance.
bioRxiv · Jul 26, 2019Cell Biology
Y.-H. T. Lin, G. P. Way, B. G. Barwick, M. C. Mariano, M. Marcoulis, I. D. Ferguson, C. Driessen, L. H. Boise, C. S. Greene, A. P. Wiita
The paper uses phosphoproteomics and transcriptomics to analyze RAS signaling in multiple myeloma, identifying distinct signaling patterns and clinical outcomes associated with NRAS and KRAS mutations.
bioRxiv · Feb 28, 2019Cancer Biology
H. H.-L. Huang, I. D. Ferguson, A. M. Thornton, C. Y. T. Lam, Y.-H. T. Lin, P. Bastola, P. Choudhry, M. C. Mariano, M. D. Marcoulis, J. Malato, P. Phojanakong, T. G. Martin, J. L. Wolf, S. W. Wong, N. Shah, , A. P. Wiita
The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.
bioRxiv · Feb 3, 2019Cancer Biology